HOFFMANN-LA ROCHE

Company snapshot

HOFFMANN-LA ROCHE maintains 286 tracked programs across Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumors, Rheumatoid Arthritis, Gastric Cancer, Carcinoma, Hepatocellular, Hepatitis C, Chronic, Not Applicable, Diabetes Mellitus Type 2, Early Breast Cancer. Momentum score: 20/100 (30-day delta: n/a). Public registry data covers pipeline

• 27 approved product(s) across US/EU regulatory metadata.
• 286 active pipeline program(s) linked via ClinicalTrials.gov.
• 286 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for HOFFMANN-LA ROCHE. Not investment advice.

• Peer + 0 momentum

  Pfizer

  TA overlap score 49.6

• Peer + 0 momentum

  Universal Integrated

  TA overlap score 47.8

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 40

• Peer + 0 momentum

  Vertex Pharmaceuticals (Australia)

  TA overlap score 40

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  Revolution Medicines

  TA overlap score 25.2

• Peer + 0 momentum

  Prime Medicine

  TA overlap score 23.4

• Peer + 0 momentum

  ALX ONCOLOGY HOLDINGS

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for HOFFMANN-LA ROCHE.

1. Jun 8, 2026 Clinical update

   MO43110 — Phase 3

2. Jun 8, 2026 Clinical update

   GO29431 — Phase 3

3. Jun 8, 2026 Clinical update

   WO29637 — Phase 3

4. Jun 8, 2026 Clinical update

   MO29872 — Phase 3

5. Jun 8, 2026 Clinical update

   YO29232 — Phase 3

View all clinical trial activity →

• What is HOFFMANN-LA ROCHE?

  Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumors. NovaPharmaNews links 286 clinical program(s), 18 drug pr

• Is HOFFMANN-LA ROCHE publicly traded?

  HOFFMANN-LA ROCHE appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does HOFFMANN-LA ROCHE develop or market?

  We link 212 drug profile(s) where HOFFMANN-LA ROCHE is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/roche-registration-limited#company-drugs.

• What are the latest developments for HOFFMANN-LA ROCHE?

  In the last 12 months our linked public records show 286 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does HOFFMANN-LA ROCHE focus on?

  HOFFMANN-LA ROCHE focuses on Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA) based on our analysis of their pipeline programs and drug development activities.